The FDA approved 177Lu PSMA-617 for prostate-specific membrane antigen-positive metastatic castration-resistant prostate ...
The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK said it has given a world-first approval to Rotop's ...
The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...
Gozellix®, after being labeled with the radioactive tracer gallium-68, is indicated for PET scanning to detect PSMA-positive lesions in men who are suspected of having metastatic prostate cancer ...
(Left) PSMA PET scans of Michael Rosenblum before treatment show prostate ... metastatic cancer is no longer visible The initial breakthrough involved using a radioactive substance, or tracer, to find ...
is effective for the treatment of men with mCRPC and PSMA-expressing disease identified on PET imaging. A subset of metastatic prostate cancers progress on hormonal therapy to a ...
Hosted on MSN14d
Telix’s prostate cancer imaging agent approved in BrazilBrazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer imaging agent. Illuccix claims to be the first prostate-specific membrane ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback